Article Text

Download PDFPDF
Deterioration after Guillain–Barré syndrome: recurrence, treatment-related fluctuation or CIDP?
  1. Robert D M Hadden
  1. Dr Robert D M Hadden, Department of Neurology, King’s College Hospital, Denmark Hill, London SE5 9RS, UK; robert.hadden{at}nhs.net

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Guillain–Barré syndrome (GBS) is usually a monophasic illness, but may recur after an interval of many years in 1–6% of patients.1 The paper by Kuitwaard et al2 from one of the pre-eminent international GBS research groups describes the largest (retrospective) series of 32 patients with recurrent GBS and the first to compare these with non-recurrent GBS (see page 56). Patients with (Miller) Fisher syndrome (FS), younger age (<30 years) and milder disease (ie, ambulant) were more likely to have a recurrence: any of these factors at least doubled the risk of recurrence. Patients with FS, pure motor or oculomotor weakness usually experienced …

View Full Text

Footnotes

  • Competing interests: None.

Linked Articles

  • Research paper
    K Kuitwaard R van Koningsveld L Ruts B C Jacobs P A van Doorn